Master Protocol for the Phase 1 Study of Cell Therapies for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma, Including Long-Term Safety Follow-Up

Protocol No
ARCELLX-ACLX-001-DDBCMA
Staff Member
Binod Dhakal
Phase
I
Summary

This project is being done to study the effects of treatment with SPRX001 protein and ARC-T cells for the treatment of relapsed/refractory multiple myeloma.
Objective
Master Protocol for the Phase 1 Study of Cell Therapies in Multiple Myeloma
Study Sites
Froedtert Hospital
Status
OPEN TO ACCRUAL
Categories
Cancer, Other Blood Related, Hematologic/Blood Related Cancers
ClinicalTrials.gov
https://www.clinicaltrials.gov/study/NCT04155749